286 related articles for article (PubMed ID: 28189365)
1. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
[TBL] [Abstract][Full Text] [Related]
2. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
3. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
6. Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak AA; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
J Clin Lipidol; 2017; 11(2):394-405. PubMed ID: 28502496
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements.
Galli C; Maggi FM; Risé P; Sirtori CR
Br J Clin Pharmacol; 2012 Jul; 74(1):60-5. PubMed ID: 22242645
[TBL] [Abstract][Full Text] [Related]
8. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
[TBL] [Abstract][Full Text] [Related]
9. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
10. The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro.
Krokan HE; Bjerve KS; Mørk E
Biochim Biophys Acta; 1993 May; 1168(1):59-67. PubMed ID: 8504143
[TBL] [Abstract][Full Text] [Related]
11. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
[TBL] [Abstract][Full Text] [Related]
12. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
13. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
14. Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State.
Maki KC; Palacios OM; Buggia MA; Trivedi R; Dicklin MR; Maki CE
Clin Ther; 2018 Dec; 40(12):2065-2076. PubMed ID: 30454850
[TBL] [Abstract][Full Text] [Related]
15. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters.
Bryhn M; Hansteen H; Schanche T; Aakre SE
Prostaglandins Leukot Essent Fatty Acids; 2006 Jul; 75(1):19-24. PubMed ID: 16806871
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
Tatsuno I
Expert Rev Cardiovasc Ther; 2014 Nov; 12(11):1261-8. PubMed ID: 25319059
[TBL] [Abstract][Full Text] [Related]
17. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Kim ES; McCormack PL
Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
[TBL] [Abstract][Full Text] [Related]
18. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
20. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.
Brunton S; Collins N
Curr Med Res Opin; 2007 May; 23(5):1139-45. PubMed ID: 17519081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
